EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Anti-CD24 antibody-nitric oxide donor conjugates bearing a self-bioorthogonal cleavable linker

Jianbing Wu, Tianyue Cheng, Jiajun Xie, Ziyu Qian, Linhua Huang, Xun Yuan, Libang Zhang, Shan Yang, Yihua Zhang, Tonglin Xu, Juan Zhang, Zhangjian Huang

Acta Pharmaceutica Sinica B · 2025-10 · 15 (10) · 5366-5386

DOI: 10.1016/j.apsb.2025.07.037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2025-10. Verfasst von Jianbing Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Center of Drug Discovery, China Pharmaceutical University, Nanjing 211198, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Double First Class University Plan, Natural Science Foundation of Xinjiang Uygur Autonomous Region, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is a highly aggressive malignancy predominantly managed via chemotherapy. Our clinical sample analysis revealed a significant correlation between elevated CD24 expression in TNBC tumor cells and patient survival rates. We developed a novel antibody-drug conjugate (ADC), named HN03, consisting of an antibody with engineered cysteines for site-specific conjugation with a low toxic nitric oxide (NO) precursor as its payload through a novel Pt(IV)-mediated bioorthogonal self-cleavable linker. HN03 specifically targets tumor cells expressing high levels of CD24, concurrently generating cisplatin and releasing NO upon activation. HN03 also exhibited potent in vitro and in vivo antitumor activity. It significantly reduced tumor growth at various doses, prevented tumor metastasis, with markedly lower toxicity than traditional chemotherapy agents. We found that a key mechanism of its action involved inducing apoptosis and endoplasmic reticulum stress, substantially decreasing the number of M2-type macrophages. Overall, HN03 stands out as a promising therapeutic option for TNBC, offering a targeted treatment with reduced side effects and the potential for improved outcomes. Furthermore, using Pt(IV) in the linker and an NO precursor as the payload enhances the versatility of the Antibody-NO donor Conjugate (ANC), offering new avenues for the design of the next generation of ADCs.

Schlagwörter

Stichwörter der Autor:innen

Antibody-nitric oxide donor conjugateBioorthogonal chemistryCD24CisplatinSelf-cleavable linkerSite-specific conjugationTriple-negative breast cancerTumor microenvironment

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines, Center of Drug Discovery, China Pharmaceutical University, Nanjing 211198, China.
  • Antibody Engineering Laboratory, School of Life Science & Technology, China Pharmaceutical University, Nanjing 211198, China.
  • School of Pharmacy, Key Laboratory of Active Components of Xinjiang Natural Medicine and Drug Release Technology, Engineering Research Center of Xinjiang and Central Asian Medicine Resources, Xinjiang Medical University…
  • Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong 226006, China.
  • Xinjiang Key Laboratory of Neurological Disorder Research, the Second Affiliated Hospital of Xinjiang Medical University, Urumqi 830028, China.

Förderung

  • Double First Class University Plan
  • Natural Science Foundation of Xinjiang Uygur Autonomous Region
  • National Natural Science Foundation of China
  • National College Students Innovation and Entrepreneurship Training Program
  • Fundamental Research Funds for the Central Universities
  • China Pharmaceutical University

Zitieren

APA

Wu, J., Cheng, T., Xie, J., Qian, Z., Huang, L., Yuan, X., Zhang, L., Yang, S., Zhang, Y., Xu, T., Zhang, J., & Huang, Z. (2025). Anti-CD24 antibody-nitric oxide donor conjugates bearing a self-bioorthogonal cleavable linker. Acta Pharmaceutica Sinica B, 15(10), 5366-5386. https://doi.org/10.1016/j.apsb.2025.07.037

Vancouver

Wu J, Cheng T, Xie J, Qian Z, Huang L, Yuan X, et al. Anti-CD24 antibody-nitric oxide donor conjugates bearing a self-bioorthogonal cleavable linker. Acta Pharmaceutica Sinica B. 2025;15(10):5366-5386. doi:10.1016/j.apsb.2025.07.037

BibTeX
@article{Wu2025,
  author = {Wu, Jianbing and Cheng, Tianyue and Xie, Jiajun and Qian, Ziyu and Huang, Linhua and Yuan, Xun and Zhang, Libang and Yang, Shan and Zhang, Yihua and Xu, Tonglin and Zhang, Juan and Huang, Zhangjian},
  title = {Anti-CD24 antibody-nitric oxide donor conjugates bearing a self-bioorthogonal cleavable linker},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2025},
  volume = {15},
  number = {10},
  pages = {5366--5386},
  doi = {10.1016/j.apsb.2025.07.037}
}
Kostenlos starten →